• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, March 7

Shasun Chemicals and Drugs Ltd announced on Tuesday that the company has received the approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK, for its WHO-CGMP formulation facility. The unit manufactures Oral Solid Dosage forms (tablet and capsules) for bulk tablets packing. With this approval, Shasun's products could be sold on commercial basis to the UK and European countries. The company's formulation plant at Pondicherry wascompleted in mid-2005. This manufacturing unit has a capacity to produce 3.6 billion tablets per annum. In a press release, Mr Vimal Kumar, Joint Managing Director, Shasun Chemicals, said the approval would enhance Shasun's capabilities to support the requirements of companies worldwide.

More Stories on : Overseas Investments | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Monsanto offers to cut trait value of Bt cotton

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line